"In the recent OCEAN (Optimal Anticoagulation for Enhanced Risk Patients Post-Catheter Ablation for Atrial Fibrillation) trial involving patients who had undergone successful catheter ablation for atrial fibrillation, Verma et al. report that the incidence of the primary trial outcome (a composite of stroke, systemic embolism, or new covert embolic stroke) was not significantly lower among those treated with reduced-dose rivaroxaban (15 mg per day) than among those treated with aspirin."
The OCEAN trial examined anticoagulation strategies in patients following successful catheter ablation for atrial fibrillation. Researchers compared reduced-dose rivaroxaban at 15 mg daily against aspirin treatment. The primary outcome measured was a composite of stroke, systemic embolism, or new covert embolic stroke. Results showed no significant difference in the incidence of these events between the rivaroxaban and aspirin groups. The trial population's characteristics, particularly the mean CHA2DS2-VASc score, present challenges in applying these findings to the broader atrial fibrillation patient population, suggesting the results may not be universally applicable.
Read at The New England Journal of Medicine
Unable to calculate read time
Collection
[
|
...
]